HK Stock Market Move | Insurance stocks collectively rebound, and insurers are shifting focus to 2026 sales. Institutions predict that the performance of the opening red envelope will exceed expectations.

10:25 02/12/2025

Insurance stocks collectively rebounded. As of the time of writing, China Taiping Insurance Holdings (02601) rose by 3.23% to HK$31.98; China Pacific Insurance Group (02328) rose by 2.15% to HK$17.55; PICC Group (01339) rose by 2.1% to HK$6.82; and China Life Insurance (02628) rose by 2.14% to HK$27.7.

Insurance stocks collectively rebounded. As of the time of writing, China Pacific Insurance (02601) rose by 3.23% to 31.98 Hong Kong dollars; PICC P&C (02328) rose by 2.15% to 17.55 Hong Kong dollars; The People's Insurance (01339) rose by 2.1% to 6.82 Hong Kong dollars; China Life Insurance (02628) rose by 2.14% to 27.7 Hong Kong dollars. On the news front, according to Securities Daily, several insurance companies have already achieved or are close to achieving their annual sales targets for 2025, with the focus gradually shifting towards the start of 2026. Dividend-type life insurance products are the main focus among the insurance products being prepared for the start of 2026. Guotai Haitong released a research report stating that the impact of real estate on insurance company asset side is limited. However, from the liability side of insurance, more and more signs indicate a bottoming out and rebound in liabilities, with a strong start expected for 2026. The firm believes that there is room for fundamental improvement in the non-banking sector, and continues to be optimistic about investment opportunities in the non-banking sector, especially in varieties benefiting from the entry of residents' funds into the market.

HK Stock Market Move | Yankuang Energy Group (01171) rose by nearly 3% recently, with its subsidiary planning to acquire all equity of a high-end bracket company for 3.45 billion yuan.

HK Stock Market Move | HIGHTIDE-B(02511) rose by over 6%, and the positive results of the HTD1801 compared head-to-head with Dapagliflozin Phase III clinical trial.

HK Stock Market Move | VISEN PHARMA-B (02561) rises by over 12% again, Longyou growth hormone is about to be approved. The company recently reached a strategic cooperation agreement with Tofflon Science and Technology Group.

HK Stock Market Move | Yankuang Energy Group (01171) rose by nearly 3% recently, with its subsidiary planning to acquire all equity of a high-end bracket company for 3.45 billion yuan.

HK Stock Market Move | HIGHTIDE-B(02511) rose by over 6%, and the positive results of the HTD1801 compared head-to-head with Dapagliflozin Phase III clinical trial.